CA Patent

CA2926999C — Pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazin-1-yl)pyrimidinyl derivatives and compositions useful for treating disorders related to kit

Assigned to Blueprint Medicines Corp · Expires 2021-10-19 · 5y expired

What this patent protects

81795633 ABSTRACT Compounds of Formula II: A (RN N N (RD)r, NJ 11 Z or pharmaceutically acceptable salt thereof are provided herein, as well as compositions thereof, which may be used for treating disorders related to mutant KIT, such as a mastocytosis, a gastrointestinal stromal…

USPTO Abstract

81795633 ABSTRACT Compounds of Formula II: A (RN N N (RD)r, NJ 11 Z or pharmaceutically acceptable salt thereof are provided herein, as well as compositions thereof, which may be used for treating disorders related to mutant KIT, such as a mastocytosis, a gastrointestinal stromal tumor or acute myeloid leukemia. Date Recue/Date Received 2020-09-24

Drugs covered by this patent

Patent Metadata

Patent number
CA2926999C
Jurisdiction
CA
Classification
—
Expires
2021-10-19
Drug substance claim
No
Drug product claim
No
Assignee
Blueprint Medicines Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.